Table 2.

Numbers of erythroblasts at different maturation stages in naive or P chabaudi AS–infected mice with or without EPO treatment




N

N + EPO*

I

I + EPO*
I: CD71highTER119low  0.20 ± 0.07a  6.93 ± 0.13b  1.97 ± 0.58c  5.79 ± 0.60d 
II: CD71highTER119high  0.42 ± 0.17a  11.27 ± 0.51b  1.23 ± 0.33a,c  2.05 ± 0.35c 
III: CD71low-medTER119high  2.43 ± 0.59a  57.60 ± 1.39b  4.43 ± 1.14a  10.93 ± 1.57c 
IV: CD71medTER119-
 
1.51 ± 0.30a
 
4.99 ± 0.09b
 
19.61 ± 2.44c
 
33.11 ± 2.22d
 



N

N + EPO*

I

I + EPO*
I: CD71highTER119low  0.20 ± 0.07a  6.93 ± 0.13b  1.97 ± 0.58c  5.79 ± 0.60d 
II: CD71highTER119high  0.42 ± 0.17a  11.27 ± 0.51b  1.23 ± 0.33a,c  2.05 ± 0.35c 
III: CD71low-medTER119high  2.43 ± 0.59a  57.60 ± 1.39b  4.43 ± 1.14a  10.93 ± 1.57c 
IV: CD71medTER119-
 
1.51 ± 0.30a
 
4.99 ± 0.09b
 
19.61 ± 2.44c
 
33.11 ± 2.22d
 

Erythroblasts were identified by double staining with FITC-conjugated anti-CD71 and PE-conjugated anti-TER119 antibodies. Region I: proerythroblasts. Region II: basophilic erythroblasts. Region III: polychromatic and orthochromatic erythroblasts. Region IV: nonerythroblast population expressing CD71. Data are means ± SEM × 106 cells per spleen for 3 to 5 mice per group. When 2 sets of data are labeled with superscripts of lowercase letters, it indicates that these 2 sets of data are statisitcally different (P < .05). Similar results were obtained in 2 independent experiments.

Abbreviations are explained in the footnotes to Table 1.

*

Naive or infected A/J mice were treated with 10 units of rmEPO per day for 3 consecutive days. Mice were humanely killed 1 day following the completion of the treatment, and spleen parameters were assessed.

or Create an Account

Close Modal
Close Modal